Perioperative Management of Antithrombotic Therapy in Common Otolaryngologic Surgical Procedures

Hsueh, Wayne D.; Hwang, Peter H.; Abuzeid, Waleed M.

doi:10.1177/0194599815600409

Cited by 28 publications

(46 citation statements)

References 129 publications

(233 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, in high‐risk thromboembolic patients, the interruption of antithrombotic treatment should be minimized. If a high‐risk patient is undergoing a procedure with low bleeding risk and low risk of major hemorrhage‐associated complications, such as awake injection laryngoplasty, the patient can safely continue antithrombotic therapy . Our study supports this: all 10 patients on warfarin due to atrial fibrillation or aortic valve replacement were continued on this therapy without any hemorrhage.…”

Section: Discussionsupporting

confidence: 73%

“…“Low risk” patients are defined as those having less than or equal to 5% annual risk. “Moderate‐to‐high‐risk” patients have an annual risk greater than 5% . Risk stratification is influenced by underlying pathology and associated disease‐related risk assessments, as defined by CHADS 2 classification (congestive heart failure, hypertension, age greater than 75 years, diabetes, previous stroke or ischemic attack) or the updated CHADS 2 ‐VASc, which includes vascular disease, age between 65 and 74 years, and female gender as predictive factors .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anticoagulation and antiplatelet therapy in awake transcervical injection laryngoplasty

2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 99%

Anticoagulation and antiplatelet therapy in awake transcervical injection laryngoplasty

2017

View full text Add to dashboard Cite

show abstract

“…Likewise, those with mechanical prosthetic valve are of consideration because they are not candidates for NOACs26. Concerned patients' medical conditions that are prone to develop thrombo-embolism are listed up in Table 329.…”

Section: Bleeding Risk Assessmentmentioning

confidence: 99%

“… 1 CHADS 2 score means congestive heart failure, hypertension, age ≥75 years, diabetes, and prior stroke/transient ischemic attack. 2 Updated version of CHADS 2 score. 3 High-risk features include atrial fibrillation, prior thromboembolism, left ventricular ejection fraction ≤35%, mitral or tricuspid valve placement, ≥2 prosthetic valves, and older aortic ball or tilting disc valves.Revised from the article of Hsueh et al (Otolaryngol Head Neck Surg 2015;153:493-503)29 with original copyright holder's permission.…”

Section: Tablementioning

confidence: 99%

See 1 more Smart Citation

Dental management of patients on anti-thrombotic agents

Lee

2018

J Korean Assoc Oral Maxillofac Surg

View full text Add to dashboard Cite

The number of geriatric patients seeking dental service is ever-rising because of increased life expectancy, also with problem of increased chronic medical conditions. One of them are patients on anti-thrombotic medication. Bleeding complication after minor oral surgery by anti-thrombotic agents is of concerns to dentists on dental management of these patients. Risk and benefit of the anti-thrombotic agents must be weighed before initiating dental procedures, which should be established as a treatment guideline. Purpose of the paper is to optimize the management of the dental patients on anti-thrombotic medication via standardization of treatment protocol of such a patient.

show abstract

AHNS Series: Do you know your guidelines? Perioperative antithrombotic management in head and neck surgery

2017

View full text Add to dashboard Cite

Head and neck surgeons are commonly faced with surgical patients who have underlying medical problems requiring antithrombotic therapy. It is difficult to achieve a balance between minimizing the risk of thromboembolism and hemorrhage in the perioperative period. Data from randomized, controlled trials are limited, and procedurespecific bleed rates are also difficult to pinpoint. The decision is made more difficult when patients with moderate-to-high risk for thromboembolic events undergo procedures that are high risk for bleeding. This is true for many head and neck oncologic surgeries. Furthermore, although elective procedures may be delayed for optimization of antithrombotic medication, emergent procedures cannot. Head and neck surgery often represents the most challenging of all these circumstances, given the potential risk of airway compromise from bleeding after head and neck surgery. K E Y W O R D Santicoagulants, antithrombotics, guidelines, head and neck cancer, perioperative | I NT ROD UCTI ONOpinions can differ among medical specialists, surgeons, and anesthesiologists regarding perioperative antithrombotic management. The purpose of this article is to review contemporary guidelines, based on the available literature, for management of antithrombotic medications in the perioperative period specific to head and neck oncologic surgery. Although general guidelines are helpful, it should be stressed that clear lines of communication among providers are essential to achieve a "right balance," especially in cases that do not fit neatly within existing guidelines.

show abstract

Perioperative Management of Antithrombotic Therapy in Common Otolaryngologic Surgical Procedures

Cited by 28 publications

References 129 publications

Anticoagulation and antiplatelet therapy in awake transcervical injection laryngoplasty

Anticoagulation and antiplatelet therapy in awake transcervical injection laryngoplasty

Dental management of patients on anti-thrombotic agents

AHNS Series: Do you know your guidelines? Perioperative antithrombotic management in head and neck surgery

Contact Info

Product

Resources

About